Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent ...

Initial results as promising as those in lupus and other non-cancer diseases driven by B c ...

China: CAR T-cell therapy, already in use for certain B-cell–driven autoimmune diseases such as lupus, has now demonstrated ...

Ameya Dravid is a postdoctoral researcher in Ankur Singh’s lab at Georgia Tech. In this postdoc portrait article, he ...

Two distinct subtypes, U-CLL C1 and U-CLL C2, were identified within IGHV-unmutated chronic lymphocytic leukemia, showing ...

The mechanism underlying how seasonal allergies recur year after year with precise timing remains largely unknown. An international team led by Professor Rudolf Valenta has identified a specific type ...

Jade Biosciences, Inc. ( JBIO) 44th Annual J.P. Morgan Healthcare Conference January 15, 2026 2:15 PM EST ...

Patients were randomly assigned on a 1:1 basis to receive teclistamab as monotherapy or physician’s choice of ...

A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.

Johnson & Johnson announces positive results from phase 3 MajesTEC-9 study of Tecvayli in patients with multiple myeloma: Raritan, New Jersey Friday, January 16, 2026, 10:00 Hrs [ ...

In A Nutshell Men have double the odds of presenting with stage III multiple myeloma compared to women, even after accounting ...